Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 3/20 | 0.32 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146463 | 0.93 | RORB (0.38) | KDM4ELMNAHTTSMN1; SMN2RXRA | |
| SCHEMBL143988 | 0.79 | MGLL (0.48) | MGLLCYP3A4 | |
| SCHEMBL145116 | 0.78 | MGLL (0.58) | MGLL | |
| SCHEMBL16564451 | 0.73 | MGLL (0.53) | KDM4ELMNAHTTSMN1; SMN2MGLL | |
| SCHEMBL122453 | 0.70 | MGLL (0.57) | MGLL | |
| SCHEMBL121537 | 0.67 | FPR2 (0.38) | KDM4E | |
| SCHEMBL16564445 | 0.67 | MGLL (0.51) | MGLLSLC6A7KCNH2 | |
| SCHEMBL912061 | 0.67 | MGLL (0.57) | KDM4ELMNAHTTSMN1; SMN2MGLL | |
| SCHEMBL912740 | 0.67 | MGLL (0.51) | MGLLSLC6A7 | |
| SCHEMBL912189 | 0.67 | MGLL (0.57) | KDM4ELMNAHTTSMN1; SMN2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8759333-B2 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | KDM4E 2642/4885LMNA 1397/4885HTT 2435/4885 |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KDM4E 1848/4885LMNA 1760/4885HTT 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.